Hepatobiliary surgery masters gathered in Guangzhou to discuss the frontier issues of minimally invasive diagnosis and treatment of hepatobiliary and pancreatic diseases

Text, photo/ Yangcheng Evening News all-media reporter Yu Yanhong

Correspondent Kan Wenjing Wei Tong

On December 11, the 2021 Annual Meeting of the 5th Guangdong Society of Hepatology Minimally Invasive Diagnosis and Treatment And the 2nd Guangdong Provincial Hepatobiliary and Pancreatic Minimally Invasive Diagnosis and Treatment Summit Forum were held in Guangzhou, sponsored by the Guangdong Hepatology Society, the Minimally Invasive Treatment Committee of the Guangdong Hepatology Society, and the Affiliated Cancer Hospital of Guangzhou Medical University. The annual meeting has built an excellent academic exchange platform, hoping to promote the scientific research level and clinical level of the hepatobiliary and pancreatic surgery team through the conference, and to bring the minimally invasive diagnosis and treatment of hepatobiliary and pancreatic diseases in Guangdong Province to a new level.

Professor Cui Shushu, president of the Affiliated Cancer Hospital of Guangzhou Medical University, said that this conference focused on the clinical research of hepatobiliary and pancreatic diseases, new technologies for treatment, and the latest progress in preoperative targeted and exempt combination translational therapy, etc., and conveyed the research trends and clinical application progress in the minimally invasive diagnosis and treatment of hepatobiliary and pancreatic diseases at home and abroad. Through this conference, a new academic platform will be built for experts in the province to jointly discuss the frontier issues of minimally invasive diagnosis and treatment of hepatobiliary and pancreatic diseases, and to promote the experience of prevention and treatment of hepatobiliary and pancreatic diseases and make new breakthroughs in scientific research.

Cui Shushu was interviewed

Cui Shu said that hepatobiliary and pancreatic diseases need standardized treatment. Liver cancer treatment is extremely complex, according to the staging, whether it is the first surgery or first intervention, or first chemotherapy or first minimally invasive treatment, the factors affecting the prognosis of liver cancer are complex and there are many treatment methods, the clinical departments that can treat liver cancer patients are hepatobiliary surgery, general surgery, transplantation, radiology (imaging), intervention, ultrasound, oncology (internal and external), liver disease internal medicine, gastroenterology, infectious diseases, radiotherapy, biological therapy, traditional Chinese medicine, etc., so it is very important to fully consider the standardized treatment of liver cancer with individual factors. At present, the international recommendation is the MDT (multidisciplinary diagnosis and treatment) model to make an individualized diagnosis and treatment plan for patients. "The promotion of the MDT diagnosis and treatment model for liver disease throughout the country will allow liver cancer patients to get the best treatment."

Professor Tang Yunqiang, chairman of the Minimally Invasive Diagnosis and Treatment Committee of the Guangdong Hepatology Society, said that a number of experts told the application experience of high-precision medical technology, relevant diagnosis and treatment guidelines and the latest research progress at home and abroad at the meeting, which not only demonstrated the excellent strength of the hepatobiliary and pancreatic surgery team in Guangdong Province, but also promoted the prevention and treatment of hepatobiliary and pancreatic in our province to a new level.

Source | Yangcheng Evening News Yangcheng Pie

Editor-in-charge | Cui Wencan